Table 2 Hazard ratios for EFS, RFS and OS according to the multivariable Cox regression models.

From: Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial

 

Event-free survival

Relapse-free survival

Overall survival

 

Hazard ratio

95% CI

p

Hazard ratio

95% CI

p

Hazard ratio

95% CI

p

Sorafenib versus placebo

0.614

0.435–0.867

0.006

0.570

0.354–0.917

0.021

0.742

0.490–1.124

0.160

Age

1.014

0.997–1.031

0.120

1.022

0.997–1.047

0.080

1.033

1.010–1.058

0.006

ELN risk favourable

0.481

0.245–0.944

0.033

0.598

0.259–1.383

0.229

0.344

0.132–0.899

0.030

ELN risk adverse

1.801

1.137–2.855

0.012

1.913

0.861–4.254

0.112

1.989

1.191–3.322

0.009

NPM1

0.373

0.224–0.621

<0.001

0.513

0.268–0.980

0.044

0.381

0.198–0.735

0.004

FLT3-ITD

0.532

0.254–1.116

0.095

1.499

0.529–4.246

0.446

0.801

0.374–1.718

0.570

NPM1 × FLT3-ITD interaction

5.715

2.068–15.80

0.001

2.811

0.737–10.72

0.130

3.782

1.124–12.72

0.032

Log10 of LDH

1.609

0.619–4.183

0.328

1.024

0.251–4.174

0.973

3.174

1.060–9.501

0.039

Log10 of WBC

1.040

0.741–1.458

0.822

1.135

0.699–1.843

0.607

0.787

0.527–1.175

0.241

sAML

0.607

0.334–1.104

0.102

0.368

0.121–1.113

0.076

0.547

0.259–1.155

0.113

tAML

0.734

0.295–1.827

0.506

1.122

0.385–3.268

0.833

1.106

0.398–3.074

0.847

Back to article page